 |
Hot Pursuit
22-Feb-23
|
|
|
|
|
|
|
|
|
|
|
|
Biocon raises 1,070 cr via NCDs
|
|
Biocon announced that the company has issued and allotted non-convertible debentures (NCDs) aggregating to Rs 1,070 crore on private placement basis in three series.
|
|
|
|
|
|
These unlisted, secured, rated, redeemable, non-convertible debentures having face value of Rs 1 lakh each allotted on 21 February 2023, will be matured on 21 February 2028.
Biocon is an innovation-led, global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases.
The biopharmaceutical company reported a consolidated net loss of Rs 41.80 crore in Q3 FY23 as against a net profit of Rs 187.10 crore in Q3 FY22. Revenue from operations jumped 35.3% to Rs 2,941.10 crore in the quarter ended 31 December 2022 from Rs 2,174.20 crore reported in the same period a year ago.
The scrip declined 0.62% to Rs 225.65 on the BSE.
|
|
|
|
Previous News |
Biocon
(
Results
-
Analysis
09-Aug-24
10:19
)
|
|
|
Biocon arm gets USFDA nod for chronic heart failure drug
(
Hot Pursuit
-
02-Sep-24
08:59
)
|
|
|
Board of Biocon appoints director
(
Corporate News
-
27-Jul-23
12:46
)
|
|
|
Biocon's Malaysia facility gets OAI status from USFDA
(
Hot Pursuit
-
18-Oct-23
08:42
)
|
|
|
Biocon Biologics receives EMA CHMP's positive opinion for YESAFILI®, an aflibercept biosimilar
(
Corporate News
-
24-Jul-23
09:17
)
|
|
|
Biocon Biologics appoints Shreehas Tambe as MD, CEO
(
Hot Pursuit
-
05-Dec-22
15:07
)
|
|
|
Biocon subsidiary announces positive CHMP opinion for aflibercept biosimilar
(
Hot Pursuit
-
24-Jul-23
08:16
)
|
|
|
Biocon's Bangalore-based API facility gets GMP certificate from EDQM
(
Hot Pursuit
-
23-Dec-22
09:31
)
|
|
|
Biocon Biologics elevates Shreehas Tambe as MD and CEO
(
Corporate News
-
05-Dec-22
14:44
)
|
|
|
Biocon Ltd soars 1.22%, rises for fifth straight session
(
Hot Pursuit
-
27-Mar-24
13:00
)
|
|
|
Biocon
(
Results
-
Analysis
17-May-24
10:41
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|